Interesting new graphic/chart from Johns Hopkins

1,702 Views | 5 Replies | Last: 5 yr ago by Squadron7
Squadron7
How long do you want to ignore this user?
AG


In this visualization, states that appear in shades of orange have experienced a growth in new cases over the past two weeks. States that appear in shades of green have seen declines in cases over the same period of time. The shade of the colors indicates the size of each state's growth or decline in new cases; the darker the shade, the bigger the change.

LINK.
SirLurksALot
How long do you want to ignore this user?
R.I.P Mississippi.
DadHammer
How long do you want to ignore this user?
AG
Excellent

CA, TX, Florida are all on the way down! 4-6 weeks and this will pave the way to normal lives!!!
Cepe
How long do you want to ignore this user?
AG
Great charts! I believe we will continue to bounce up and down until burnout or herd immunity is reached.

I also believe the bounces will have less and less of a peak.

It's unfortunate but it needs to pass through the population and the bounces are needed from a macro perspective. As long as the hospitals aren't overrun it seems to me most areas are managing it appropriately.
Cepe - its pronounced "Ceep" and stands for my initials - CP.
JClark97
How long do you want to ignore this user?
AG
Good post OP, and good to see Texas on the decline.
DeangeloVickers
How long do you want to ignore this user?
AG
Gompertz curve



Squadron7
How long do you want to ignore this user?
AG
Cepe said:

Great charts! I believe we will continue to bounce up and down until burnout or herd immunity is reached.

I also believe the bounces will have less and less of a peak.

It's unfortunate but it needs to pass through the population and the bounces are needed from a macro perspective. As long as the hospitals aren't overrun it seems to me most areas are managing it appropriately.

Which was the original goalpost position, IIRC.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.